A GSK-3b modulator delays photoreceptor cell death and preserves visual function in the rd10 mouse model of retinitis pigmentosa

Abstract

Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal dystrophies that lead to blindness. Photoreceptor cell death, reactive gliosis and retinal inammation are common features in animal models of the disease. The enzyme Glycogen Synthase Kinase-3 Beta (GSK-3b) is involved in inammatory processes associated to diverse neurodegenerative pathologies. The aim of our study is to test in the rd10 mouse whether the GSK-3b inhibitor VP3.15 (a small heterocyclic molecule) is a potential therapeutic treatment for RP.